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The histone methyltransferase Mixed Lineage Leukemia (MLL) is
essential to maintain hematopoietic stem cells and is a leukemia
protooncogene. Although clustered homeobox genes are well-char-
acterized targets of MLL and MLL fusion oncoproteins, the range of
Mll-regulated genes in normal hematopoietic cells remains un-
known. Here, we identify and characterize part of the Mll-depen-
dent transcriptional network in hematopoietic stem cells with an
integrated approach by using conditional loss-of-function models,
genomewide expression analyses, chromatin immunoprecipitation,
and functional rescue assays. TheMll-dependent transcriptional net-
work extends well beyond the previously appreciated Hox targets,
is comprised of many characterized regulators of self-renewal, and
contains target genes that are both dependent and independent of
the MLL cofactor, Menin. Interestingly, PR-domain containing 16
emerged as a target gene that is uniquely effective at partially res-
cuing Mll-deficient hematopoietic stem and progenitor cells. This
work highlights the tissue-specific nature of regulatory networks
under the control of MLL/Trithorax family members and provides
insight into the distinctions between the participation of MLL in
normal hematopoiesis and in leukemia.
proliferation | HSC | epigenetics
Epigenetic regulation is an important mechanism by which geneexpression fidelity is maintained during development. The tri-
thorax-group (trx-G) and Polycomb-group (Pc-G) genes encode
epigenetic factors that act as opposing regulators of clustered ho-
meobox (Hox) gene expression and of axial patterning in most
metazoa (1, 2). In addition, numerous studies implicate Pc-G and
trx-G homologs in mammals in the maintenance of broader gene
expression programs in embryonic and tissue stem cells and in cancer
(1, 2). Because of the reversible nature of epigenetic lesions in cancer,
targeting oncogenes and tumor supressors that use epigenetic
mechanisms is a promising an approach for targeted therapy (3).
The human protooncogeneMixed Lineage Leukemia (MLL) was
the first mammalian trx homolog identified because of its charac-
teristic rearrangement in ∼70% of infant leukemia. Rearrangement
of the human MLL gene by chromosomal translocation also occurs
at a lower frequency in childhood acute lymphoblastic leukemia
(ALL), acute myelogenous leukemia (AML), and treatment-related
and de novoAML in adults (4, 5).Most translocations produceMLL
fusion oncoproteins that retain the chromatin-targeting N terminus
and acquire a transcriptional effector domain from the C-terminal
partner. Partner proteins frequently recruit protein complexes that
result in increased histoneH3 lysine 79 dimethylation atMLL-fusion
targets, overexpression of these target genes, and leukemic trans-
formation (6). Because many of the chromatin-targeting motifs are
shared between oncogenic MLL fusions and wild-type MLL, tar-
geting of MLL-fusion oncoproteins will also require a thorough
understanding of normal MLL-dependent regulatory pathways.
Wild-type MLL exists in cells as part of a large multiprotein,
chromatin-associated complex that contains chromatin remodeling
and histone acetylation/methylation activities (7, 8). MLL itself is
thought to regulate genes in part through a highly conserved histone
methyltransferase motif, the Su(var)3-9, Enhancer of Zeste, and
Trithorax (SET) domain. MLL, like Trithorax, maintains precise
domains ofHox gene expression during embryo development (9, 10).
In addition, MLL has been shown to regulate other tissue-specific
processes in immune, hematopoietic, vascular, and neural cell types
(11–14). Germ-line disruption of Mll is generally embryonic lethal
with multiple developmental defects (9, 15–17); however, condi-
tional deletion ofMll in specific cell types revealed unique functions.
For example, hematopoietic-specific deletion of Mll demonstrated
that it is essential for maintaining hematopoietic stem and pro-
genitor cells (HSPCs), but dispensable for lineage-committed pre-
cursors (13, 18, 19). The breadth of target genes regulated byMLL in
specific tissues is largely unknown, although Hox genes are consis-
tently down-regulated in many Mll-deficient cell types (9, 13, 14).
In this study, we investigate the molecular circuitry underlying the
critical role of Mll in maintaining hematopoiesis as a means to un-
derstand trx-G function in normal and pathologic gene regulation.
We used inducible loss-of-function models to identify hematopoietic
stem cells (HSC)-specific MLL-regulated genes and delineated
a network of transcriptional regulators that are direct transcriptional
targets of MLL. We then tested reexpression of a subset of these
genes inMll-deficient hematopoietic cells to determine the epistatic
relationships among transcriptional targets, to identify cross-regula-
tory relationships, and assess their individual ability to restore
function inMll-deficient cells. These studies reveal a coherent MLL
pathway that coordinates self-renewal, proliferation, and lineage-
specific gene expression fidelity in HSCs. Furthermore, this work
distinguishes the MLL-dependent transcriptional network from
that controlled by MLL fusion oncoproteins in leukemia.
Results
Short-Term Consequences of Mll Deletion in HSCs. To identify Mll-
dependent genes involved in maintaining HSCs, we analyzed dif-
ferentially expressed transcripts afterMll deletion. Lineage-negative,
stem cell antigen-1 (Sca-1)+, c-Kit+, CD48− (LSK/CD48neg) HSC-
enriched cells from the bone marrow (BM) of polyinosinic:poly-
cytidylic acid (pI:pC)-injected control MllF/F or Mx1-cre;MllF/F ani-
mals were purified 6 d after the first pI:pC injection, the optimal
timing for Mll deletion, cell yield, and down-regulation of ho-
meobox protein a9 (Hoxa9), a bona fide Mll target gene (13).
Assessment of normalized gene expression differences between
control and Mll-deficient LSK/CD48neg cells revealed 1,935 dif-
ferentially expressed genes using Significance Analysis of Micro-
arrays (which does not impose a fold cutoff; Fig. 1) (20). Functional
classification of genes differentially expressed inMll-deficientHSCs
compared with controls resulted in three global observations: (i)
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more genes were up-regulated than down-regulated, (ii) a subset
of erythroid-specific genes were up-regulated, and (iii) the largest
category of annotated down-regulated genes was comprised of
transcriptional regulators.
Among the up-regulated genes, the largest group corresponds
to HSC proliferation and ribosome or mitochondrial biogenesis
(Fig. 1A and Dataset S1). Up-regulation of genes involved in ri-
bosome biogenesis reflected the greater proportion of cyclingMll-
deficient LSK/CD48neg cells (45% G0 in Mll-deleted cells versus
75%G0 in controls; ref. 13). Ten percent in this category and 17%
in the mitochondrial group were also identified in proliferating
HSCs (21), (Dataset S1). Thus, many of the up-regulated genes
reflect the expected changes based on the proliferation state of
Mll-deficient LSK/CD48neg cells. Unexpectedly, 5% of the genes
that were up-regulated inMll-deficient LSK/CD48neg cells encode
erythroid-specific proteins including transcriptional regulators
such as GATA binding protein 1 (Gata1) and Kruppel-like factor
1 (Klf1), as well as spectrin, Kell protein (Kel), Erythropoietin re-
ceptor (EpoR), and hemoglobin biosynthesis genes (Dataset S1).
Gene set enrichment analysis (GSEA) also identified a GATA1-
induced gene signature and a tendency toward erythroid identity
(Fig. S1 A and B). The up-regulation of erythroid genes was vali-
dated by using an independent in vitro Mll deletion system, illus-
trating that the scale of gene up-regulation was consistent with
derepression rather than full induction of erythroid genes (Fig. S1
C and D). Furthermore, this derepression was not sufficient to
impart erythroid fate as demonstrated by colony assay (Fig. S1E).
Derepression of erythroid genes likely occurs through an indirect
mechanism, thus we focused on the down-regulated genes as po-
tential MLL effectors in the maintenance of HSCs.
Identifying an Mll-Dependent Transcriptional Network. Transcrip-
tional regulators comprised the largest single annotated category of
down-regulated genes inMll-deleted LSK/CD48neg cells (Fig. 1B and
Dataset S2). Because many of these regulators are highly expressed
in HSCs relative to more differentiated cell types (22), we asked
whether Mll-deficient HSCs exhibit a global shift in cell fate by
assessing the relatedness of our gene expression data to other he-
matopoietic populations (23, 24). This analysis showed an enrich-
ment of erythroid identity as described earlier, but did not suggest
that HSCs were generally differentiated, because HSC and multi-
potent progenitor signatures were equivalently enriched by GSEA
(Fig. S1F). Mll itself (Fig. S1G) and well-characterized MLL
targets such as Hoxa9 were down-regulated although the majority
of the genes in this category were not previously known to be Mll
targets (Fig. 1C). We confirmed the Mll dependence for all an-
notated transcription factors >2.5-fold down-regulated by quan-
titative RT-PCR (RT-qPCR) using independently sorted samples
fromMx1-cre;MllF/F animals (Fig. 1D), as well as cells in whichMll
was deleted in vitro by using 4-hydroxytamoxifen (4-OHT; Fig.
1E). Each inducible knockout model has its characteristic limi-
tations, so to discover genes that were truly Mll-dependent, we
only pursued genes down-regulated in both Mx1-cre and ER-cre
systems.Of the annotated transcription factors down-regulated>2.5-
fold (Fig. 1C), MDS and Evi1 complex locus (Mecom), Prdm16, Pre-
B cell leukemia homeobox protein 1 (Pbx1), Eyes absent homolog 1
(Eya1) and Hoxa9 were consistently Mll-dependent (Fig. 1E). Tri-
partate motif-containing 30b (Trim30b) is not characterized, so we
focused on the other five genes for the following studies.
Several of the transcriptional regulators identified above individ-
ually play critical roles in HSC homeostasis. For example, the pro-
teins encoded by the Pbx1, Prdm16, andMecom genes act to restrain
HSC proliferation and/or promote self-renewal (25–29), as has been
demonstrated for Mll (13, 18). Interestingly, Mecom and Prdm16
were not Mll-dependent in fibroblasts or in Mll knockout embryos
overall, despite coexpression of Mll and these genes (Fig. S2).
MLL Binds Directly to the Promoter Regions of a Subset of Mll-
Dependent Genes. Mll and its homolog Trithorax typically act to
maintain expression of their direct target genes (30), thus we evalu-
ated the down-regulated transcription factors as potential direct
MLL targets. To assess whether MLL acts directly to promote ex-
pression of the identified transcriptional regulators, we used a mini-
ChIP procedure optimized for 5 × 104 BM cells (31). Based on
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Fig. 1. Identification of Mll-regulated genes in HSCs. General overview of
genes up-regulated (A) or down-regulated (B) in Mll-deficient LSK/CD48neg
cells compared with controls. Cells were sorted from pI:pC-injected control
MllF/F or Mx1-cre;MllF/F animals at day six. Gene Ontology assignments were
based on the criteria in Datasets S1 and S2. (C) The top down-regulated
transcription factors inMll-deficient LSK/CD48neg cells listed by fold reduction
(see also Dataset S2). (D) RT-qPCR validating down-regulated genes in in-
dependent control MllF/F (blue) or Mll-deficient (red) LSK/CD48neg cells, n = 8
animals per genotype; ND, not detected. (E) RT-qPCR validation of transcripts
in LSK cells sorted from control ER-cre;MllF/+ (blue) or ER-cre;MllF/F animals
(red) cultured for 72 h after initiating Mll deletion. Relative expression levels
were determined by normalizing to Gapdh, n = 4 animals per genotype. Error
bars represent 95% confidence interval (CI). *P ≤ 0.07, **P ≤ 0.05. ER-cre,











































Fig. 2. MLL binds directly to the promoter regions of a subset of genes
identified by expression array. ChIP results demonstrating specific enrich-
ment at the Mecom locus (Mds1 and Evi1 start sites) and the Prdm16, Pbx1,
and Eya1 promoter regions. Anti-MLL C-terminal (black) or control (anti-
GAL4, gray) antibodies were used for ChIP, and enrichment was determined
by using quantitative PCR assays. Amplicon position is indicated relative to
the TSS for each gene. Results using additional primers surrounding the TSS
are shown in Fig. S4. Data represents averages ± SEM for two to four PCR
replicates and are representative of at least four independent experiments.



















sites (TSS) in cell lines (32, 33), we assessed MLL binding within 2
kb of the TSS by using 3–5 amplicons per gene.Mll-dependence
was similarly observed in the BM lineage-negative (linneg) pop-
ulation and LSK cells (Fig. S3A). Control ChIP experiments
demonstrated MLL binding to the Hoxa9 but not Gapdh TSS
regions (Fig. S3B). Using linneg BM cells, we observed specific
MLL binding around each TSS of the Mecom locus [both Mye-
lodysplastic syndrome 1 (Mds1) and Ecotropic virus integration
site 1 (Evi1) promoter regions], as well as the Prdm16, Pbx1, and
Eya1 genes (Fig. 2 and Fig. S3 C–G). Interestingly, we did not
observe MLL binding to the Early growth response 1 (Egr1) pro-
moter (Fig. 2B and Fig. S3H), consistent with the observation
that this gene was not Mll-dependent in both model systems (Fig.
1E). Therefore, we conclude that like Hoxa9, the expression of
Mecom, Prdm16, Pbx1, and Eya1 is maintained directly by MLL in
normal linneg BM cells.
Only a Subset ofMll-Dependent Genes Are Affected byMen1 Deletion.
MLL itself does not harbor sequence-specific DNA binding motifs.
One important chromatin-targeting mechanism occurs through an
N-terminal interaction with Menin and p75/lens epithelium-
derived growth factor (LEDGF), thought to be essential for tar-
geting wild-type MLL to promoter regions based on studies using
MLL fusion oncoproteins (34). To understand how the MLL
complex localizes to its targets in HSCs, we assessed the Menin
dependence of Egr1, Hoxa9, Prdm16, Mecom, Pbx1, and Eya1.
Consistent with a previous study (35), we found that Hoxa9 ex-
pression was reduced in Menin (Men) 1-deficient LSK cells. In-
terestingly, Mecom and Eya1 were slightly reduced, but the latter
was not statistically significant (Fig. 3A). Despite efficient excision
ofMen1 (Fig. 3B), Prdm16 and Pbx1 levels were not affected (Fig.
3A), suggesting that a subset of HSC-specificMll-dependent genes
do not require Menin. These data demonstrate that the MLL
complex differentially requires the Menin chromatin-targeting
cofactor to regulate distinct classes of target genes.
Structure of the Mll-Dependent Transcriptional Network. We consid-
ered that some of theMll-dependent transcriptional regulators act
in interconnected pathways to modulate HSC function. For ex-
ample, it has been reported that overexpression of Evi1 up-regu-
lates Pbx1 in c-Kit–enriched BM cells (36). To identify potential
expression interrelationships and determine whether the identi-
fied genes represent a linear or branched pathway downstream of
MLL, we overexpressed Hoxa9, Prdm16, Eya1, Pbx1, or Mecom
isoforms (Mds1-Evi1 and Evi1) in wild-type or Mll-deficient LSK
cells and assessed the effect on other genes in this network 48 h
later. Focusing first on the effects of overexpression in wild-type
cells, we found that Hoxa9 could increase levels of Prdm16, Evi1
could increase both Prdm16 and Hoxa9, and Prdm16 could in-
crease Hoxa9 levels. For Mll-deficient LSK cells infected with the
empty retrovirus, we observed reduced expression of Hoxa9,
Prdm16, Mecom, Pbx1, and Eya1 (Fig. 4, empty) as observed in
unmanipulated Mll-deficient LSK cells (Fig. 1). However,
reexpression of Hoxa9, Prdm16, Eya1, or Pbx1 did not
restore expression of the other tested genes to wild-type levels in
Mll-deficient LSK cells (Fig. 4). In contrast, expression of either of
the Mecom isoforms altered the expression of other genes in this
network in Mll-deficient LSK cells. Evi1 expression increased
Prdm16 and Hoxa9 transcripts in Mll-deficient LSK cells back to
the wild-type levels (Fig. 4 A and B). Mds1-Evi1 suppressed
Prdm16, Hoxa9, Pbx1, and Eya1 expression in wild-type cells to the
low levels observed inMll-deficient LSK cells (Fig. 4A, B,D, and E),
consistent with previous observations thatMds1-Evi1 and Evi1 have
opposing activities on hematopoietic differentiation and cytokine-
stimulated growth (37, 38). These data illustrate that overexpression
of individual transcription factors can influence the expression levels
of other regulators in this network primarily in wild-type LSK cells,
yet in most cases cannot restore normal levels of any of the network
genes inMll-deficient cells. The exception isEvi1, which is capable of
restoring the expression of two of the five genes in this network in
Mll-deficient LSK cells. Taken together, these data exclude that
these transcriptional regulators are organized in a linear pathway
downstream of MLL and, instead, suggest that they each perform
independent functions as downstream effectors of MLL.
Prdm16 Exhibits a Unique Capacity to Partially RescueMll-Deficient Cells.
One to two weeks after inducing cre, the attrition of BM cells in
Mx1-cre;MllF/F animals results in animal death accompanied by
multiple defects in HSPCs (13). To evaluate the relative functional
importance of the identified Mll targets, we assessed whether re-
expression of individual genes could rescue Mll-deficient cell
attrition from BM chimeras. To this end, the Mll target genes
identified above were overexpressed individually in sorted LSK
cells from uninduced control MllF/F or Mx1-cre;MllF/F mice, then
engrafted into lethally irradiated recipients together with un-
infected wild-type BM cells. After stable engraftment,Mll excision
was induced by pI:pC injection and the persistence ofMll-deficient
BM cells expressing the reintroduced gene was determined 2 wk
later (Fig. 5A). Thus, in this assay, “rescue” is defined as the selec-
tive persistence of retrovirus-infected cells within the population
of Mll-deleted cells (Fig. S4A). The use of Mll itself as a positive
control was precluded by the large size of the Mll transcript
(>11 kb), because it could not be packaged into a retrovirus.
Upon Mll deletion, uninfected or empty retrovirus-expressing do-
nor cells were lost rapidly from chimeric animals as expected (Fig. S4
B and C). Hoxa9 overexpression resulted in the expansion of donor-
derived cells in chimeras (Hoxa9 versus empty) but also Hoxa9
expressing Mll-deficient cells were protected from attrition, as evi-
denced by their overrepresentation in the Mll-deficient population
(Fig. 5B, red versus blue). Surprisingly, Prdm16 reexpression resulted
in themost significant rescue ofMll-deficient cells. Despite its greater
ability to influence other network genes, reexpression of Evi1 only
marginally protectedMll-deficient cells fromattrition, andMds1-Evi1,
Pbx1, andEya1 had no specific activity in this assay (Fig. 5B). Because
of the low contribution of Evi1-expressing cells in chimeras, we con-
sidered in this case that overexpression may suppress hematopoiesis
overall, but we found that a retrovirus producing ∼10-fold less Evi1
produced similar results (Fig. S4 E–H). CompleteMll deletion in the
persisting cells of chimeras was confirmed by a quantitative genomic
PCRassay (Fig. S4D).We found that retroviral overexpression of the
individual genes resulted in a similar contribution to lymphoid and
myeloid lineages, with the exception being the suppression of
B-lymphopoiesis by Prdm16 (Fig. S4I) as has been noted (26). Taken
together, these data suggest that in addition toHoxa9, Prdm16 is an
important direct target of MLL in HSCs and is capable of partially
rescuing Mll-deficient hematopoietic cells from attrition in BM chi-
meras without restoring the entire transcriptional network.
Prdm16 Can Correct the Intrinsic Proliferation Defect of Mll-Deficient
HSCs. To determine the mechanism by which Prdm16 partially














































Fig. 3. Menin loss affects somebutnotallMLL targets in LSK cells. (A) RT-qPCRof
Mll-regulated genes in LSK cells sorted from control ER-cre;Men1F/+ (black) or ER-
cre;Men1F/F cells (white) cultured for 72 h after initiatingMenin deletion. Expres-
sion levelswerenormalized to rRNA. (B)Menin transcript levels in LSK cells treated
as in A. Error bars represent 95% CI; n = 4–8 animals per genotype. **P ≤ 0.05.
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Prdm16 reexpression on LSK cell proliferation. We demonstrated
that more Mll-deleted LSK cells are in S phase compared with
wild-type, and that the CD48neg subset of these cells were largely in
G1/S rather than G0 (13). Thus, we first assessed whether we could
recapitulate any aspects of the hyperproliferative phenotype in
vitro, then assessed the impact of Prdm16 in this setting.
To directly assess proliferation kinetics in vitro, wild-type (MllF/F)
or Mll-deleted (Mx1-cre;MllF/F) LSK/CD48neg cells were sorted
from pI:pC-injected animals, deposited into wells as single cells
and cultured in serum-free medium containing cytokines to main-
tain HSC identity and function (39) (Fig. 6A). Importantly, the
percentage of surviving clones was similar between wild-type and
Mll-deleted cells (Fig. S5A), confirming previous observations that
apoptosis is not induced in Mll-deleted HSPCs (13). Integrating
individual observations for 158 wild-type and 240 Mll-deleted
LSK/CD48neg cells, we found that the proliferation kinetics of the
latter were consistently more advanced than wild type (Fig. 6E).
After 48 h, the mode (greatest number of cells) of Mll-deleted
LSK/CD48neg clones had progressed approximately one-half a
division further than the wild-type clones (Fig. 6C), and by 72 h,
themode was one full cell division ahead (Fig. 6D). To address the
possibility thatMll-deficient LSK/CD48neg cells exhibit earlier cell
division because more are initially in G1/S compared with wild
type, we performed higher resolution studies examining the initial
three cell divisions (Fig. 6E). We found that Mll-deficient LSK/
CD48neg cells enter the cell cycle earlier at all cell divisions; in fact,
Mll-deficient cells had a shorter cell cycle (∼1 h) than wild-type
cells (Fig. S5B). Therefore,Mll-deficiency results in a cell-intrinsic
increase in proliferation that is recapitulated in vitro in conditions
that maintain HSC identity. This system likely models the in-
creased proportion of LSK cells in S phase we observed in vivo but
does not represent the defect in maintaining G0 (13).
To investigate whether Prdm16 reexpression influenced the
proliferation phenotype observed in Mll-deficient cells, we sorted
LSK cells from control ER-cre;MllF/+and ER-cre;MllF/F mice, ret-
rovirally introduced Prdm16, and concurrently incubated with
4-OHT to induce Mll deletion (Fig. 6F). ER-cre;MllF/F cells in-
fected with an empty control retrovirus displayed greater cell ac-
cumulation than the ER-cre;MllF/+ control cells, consistent with
the single cell observations. However, Prdm16 reexpression re-
stored the growth of Mll-deficient LSK cells to within the normal
range of the control LSK cells (Fig. 6G). Together, these data
suggest that the mechanism by which Prdm16 can correct Mll
deficiency is, in part, by restraining proliferation within HSPCs.
Discussion
Using two complementary conditional knockout models (Mx1-cre
and ER-cre), we have identified genes that are consistently Mll
dependent in HSC-enriched cell populations. The acute nature of
Mll deletion and the use of highly purified cells resulted in the
identification of a succinct list of transcriptional regulators with a
high level of reproducibility and enrichment for genes that control
self-renewal and proliferation specifically in HSCs. Thus, we refer
to this set of genes as core components of the MLL HSC-specific
transcriptional network. Among the down-regulated genes,
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Fig. 4. Effect of reexpression of individual Mll targets
on others in the network. RT-qPCR of genes in LSK cells
reexpressing the cDNA indicated below each set of
bars. Cells were produced in vivo by pI:pC injection,
sorted 6 d later, then infected with a retrovirus with-
out an added cDNA (empty) or cDNA as indicated. Two
days later, retrovirally infected cells were sorted and
RT-qPCR assays were performed. (A) Prdm16 expres-
sion levels in control MllF/F (blue) or Mll-deficient (red)
LSK cells infected with the retrovirus indicated below
each set of bars. Expression levels were normalized to
the average expression level empty retrovirus-infected
MllF/F cells and to Gapdh in each sample. Expression of
Hoxa9 (B), Mecom transcripts (C), Pbx1 (D), and Eya1
(E) were analyzed and normalized as in A. Dashed
lines indicate the average expression level in wild-type
orMll-deficient, empty retrovirus infected cells; four to
five animals per genotype were used for each experi-
ment, and error bars represent 95% CI. P values are
shown for the comparison between pairs of empty
vector and Evi1-expressing cells, calculated with the






















































Fig. 5. Reexpression of Prdm16 partially rescues Mll deficiency. (A) Experi-
mental scheme to determine effects of reexpression of Mll-dependent genes.
LSK cells were sorted from control MllF/F or Mx1-cre;MllF/F donor animals then
infected with the indicated retrovirus. The entire pool of infected and un-
infected cells was transplanted into irradiated recipients, which were analyzed
6 wk later. (B) Results of reexpression of each individual gene in control MllF/F
(blue) or Mll-deficient LSK cells (red); each point represents an individual re-
cipient animal, n = 3–10 recipients per condition. The percentage of donor-
type (CD45.1+) BM cells that are GFP+ or hCD4+ 2 wk after Mll deletion is
shown. Data are representative of three independent experiments. *P ≤ 0.05
was calculated by using the Wilcoxon rank-sum test.



















interconnected Mll-regulated transcriptional nodes, with Prdm16
exhibiting the greatest activity to replaceMll function in HSCs.We
tested these genes individually by overexpression to uncover
dominant nodes downstream of Mll, but our data are consistent
with the concept that this network functions coordinately to
sustain HSC homeostasis through diverse functions, hence the
inability of any individual gene to completely replace Mll in the
gene expression or functional assays. In fact, each of these genes
has distinct targets and loss-of-function phenotypes (25, 27–29,
40). Ultimately, identification of the minimal network of genes
sufficient to replace Mll function will require simultaneous ex-
pression of physiologic levels of multiple genes.
Given the mechanisms by which MLL family members regulate
gene expression, one surprising finding was the large number of
up-regulated genes in Mll-deficient HSCs. However, the majority
of these genes reflect the enhanced proliferation that we observe
in Mll-deficient HSC-enriched populations in vivo, a finding that
we also observe at single-cell resolution in the current study. The
direct connection between Mll and enhanced proliferation in
HSCs could be explained by three mechanistically distinct hy-
potheses. First, Pbx1,Mecom, and Prdm16 have all been suggested
to suppress HSC proliferation, based on the analysis of hemato-
poietic populations in the corresponding knockout animals (25,
27, 29). Thus, the reduction in these three factors would be pre-
dicted to result in unrestrained proliferation, specifically in HSCs.
Interestingly, responsiveness to TGFβ signaling is attenuated
in hematopoietic cells from each of these knockouts (25, 29, 41),
suggesting that the overall effect may have a significant impact
on TGFβ signaling (Fig. S5 C and D). Alternatively, a distinct
mechanism has been proposed to link Mll to proliferation in the
setting of DNA damage. In this case, DNA damage-induced delay
in origin of replication activation is enforced by wild-type MLL
(42). In our conditional knockout system, it is possible that the loss
ofMLL (even in the absence of overt DNAdamage) also results in
unrestrained origin activation, a more rapid S phase, and shorter
overall cell cycle duration. Finally, a recent demonstration that
Mds1-Evi1 and Prdm16 are H3K9 monomethylases (43) suggests
that global derepression of heterochromatinized genes could
potentially have a broad impact on the suppression of proliferation
or erythropoiesis in Mll-deficient HSCs.
By identifying this transcriptional network, we discovered three
important features of this HSC-specific Mll pathway. First, some
(e.g.,Hoxa9, Mecom), but not all (e.g., Pbx1, Prdm16), of the direct
Mll target genes also require the cofactor Menin. This finding
illustrates that MLL uses distinct chromatin-targeting motifs for
distinct categories of its direct target genes. Second, the genes
identified here as Mll dependent in HSCs are not universally
regulated byMll in other tissues, with the exception ofHoxa9. This
observation suggests that tissue-specific targeting and restriction
mechanisms are behind the tissue-specific activity of MLL family
members. Third, we note that not all of the HSC-specific, Mll
target genes are up-regulated in leukemia, possibly reflecting the
distinction between the chromatin targeting/activation mecha-
nisms used by fusion oncoproteins in contrast to those used by
wild-type MLL. For example, it is clear that Hoxa9 is consistently
overexpressed in MLL translocation leukemia, whether T-cell
ALL (T-ALL), B-cell ALL (B-ALL), or AML (44–46). Evi1 and
Eya1 have recently been implicated as targets of MLL fusion
oncoproteins in some leukemia subsets (33, 47), but they are not
consistently up-regulated in either ALL or AML harboring an
MLL rearrangement. Prdm16 is not up-regulated in MLL-trans-
location leukemia yet can be activated by retroviral insertion in
leukemia by translocation in other contexts, therefore has leuke-
mogenic potential (48). Thus, our data begin to delineate a normal
and reversible HSC-specific maintenance pathway, of which a se-
lective portion is subverted to result in leukemia. Interestingly,
Hoxa9, Mecom, and possibly Eya1 are theMll-dependent genes we
found to be affected by Menin loss, providing an intriguing con-
nection between chromatin-targeting mechanism and leukemo-
genic versus normal HSC regulatory networks. The selective
dependence on particular protein–protein interactions may render
leukemia-specific gene programs driven by Mll-fusion oncogenes
more sensitive to inhibitors than normal HSCs, as suggested by the
study of compounds that disrupt theMenin–MLL interaction (49).
Our work illustrates that MLL family members control exquisitely
tissue-specific gene programs despite their ubiquitous expression
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Fig. 6. The intrinsic proliferation defect ofMll-deficient HSCs is corrected by reexpression of Prdm16. (A) Scheme to determine proliferation kinetics of individual
LSK/CD48neg cells.Mlldeletionwas performed in vivo, and double-sorted LSK/CD48neg cells were deposited at 1 cell perwell. Cell divisionswere scored every 24h. (B–
D) Cumulative proliferation data from individual controlMllF/F (blue) orMll-deficient LSK/CD48neg cells (red). Data represent 158 controlMllF/F and 240Mll-deficient
cells; n= 3–5 animals per genotype. The difference betweenmodes of each line is indicated by grayfill. The Pearson’s χ2 test was performed to determine statistical
significance, shown on B–D. (E) Higher-resolution proliferation kinetics of control MllF/F (blue) or Mll-deficient LSK/CD48neg cells (red). Cells were prepared as in
A, n= 2–3 animals per genotype, 93 controlMllF/F and 38Mll-deficient cells. The percentage of cells past the first, second, and third divisions are graphed separately
(1°, 2°, 3°). (F) Scheme to determine the impact of Prdm16 reexpression inMll-deficient LSK cells. (G) Accumulation of LSK cells expressing an empty (solid) or hCD4-
Prdm16 retrovirus (dashed). LSK cells were sorted from control ER-cre;MllF/+ (blue) or ER-cre;MllF/F animals (red), cultured in 4-OHT during the retroviral infection to
induce Mll deletion then enumerated every 24 h for 3 d. Data represent averages ± 95% CI, n = 4 animals per genotype, 3 replicates per time point.
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patterns, underscoring the complexity of mechanisms that must be
used to regulate diverse gene expression programs in vivo.
Materials and Methods
Mice and in Vivo Induction of cre Recombinase. Mx1-cre;MllF/F animals and cre
induction have been described (13). Men1F/F mice (kind gift of Matthew L.
Meyerson, Harvard Medical School, Boston, MA) were back-crossed by using
the DartMouse speed congenic facility then crossed to the ER-cre strain.
Flow Cytometry, Cell Sorting, and Culture. Flow cytometry and cell sorting were
performed on a FACSCalibur and FACSAria, respectively (BD Biosciences). Data
were analyzed by using FlowJo software (Tree Star). Fluorochrome-labeled
antibodies and procedures are detailed in SI Materials and Methods.
Plasmids, Retroviral Infection, Cell Culture, and Transplantation.Murine stem cell
virus (MSCV)-based retroviral expression plasmids were constructed by using
cDNAs obtained or cloned as described in SI Materials and Methods. Viral
supernatants were prepared by cotransfection, and sorted LSK cells were in-
fected by using retronectin (Takara). Retrovirally infected cells were cotrans-
planted into lethally irradiated (950 Rads, split dose) C57BL/6J female mice.
For proliferation assays, LSK and LSK/CD48neg cells were cultured in HSC expan-
sion medium [StemSpan Serum Free Expansion Medium (SFEM); 300 ng/mL
recombinant murine (rm) SCF, 20 ng/mL rmIL-11, and 4 ng/mL rmFlt3L; StemCell
Techologies and R&D Systems]. To induce deletion using the ER-cre strain, HSC
expansion medium was supplemented with 300–400 nM 4-OHT (Sigma).
ChIP. Rabbit polyclonal anti-MLL C terminus (50) or anti-Gal4 (Santa Cruz; SC-
577) antibodies were used for ChIP by using linneg or LSK cells (31) with
refinements as indicated in SI Materials and Methods. Primer sequences and
genomic positions are described in Dataset S3.
Microarray Sample Preparation and Data Analyses. Affymetrix microarray anal-
yses were performed by using sorted LSK/CD48neg cells from fiveMllF/F orMx1-
cre; MllF/F mice 6 d after cre induction. Detailed methods and bioinformatic
analyses are found in SI Materials and Methods and Dataset S4.
Statistical Analyses. Unless indicated otherwise, the unpaired Student t test
was used to determine significance, and error bars represent 95% CI.
Statistical analyses were performed by using Excel (Microsoft) or Prism
(GraphPad) Software.
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